BMS & Gladstone Enter Discovery Partnership in Alzheimer's Disease

By identifying targets that prevent or reverse Tau dysfunction, BMS and Gladstone hope to identify novel therapeutic strategies to modify the course of the disease.

Bristol-Myers Squibb Company and the Gladstone Institutes announced Thursday the formation of a discovery-based research collaboration to identify and validate novel targets in Alzheimer's disease.

Under the agreement, Bristol-Myers Squibb will fund Gladstone's research efforts to identify targets that affect Tau dysfunction.

Tau is a protein that binds the cell's internal skeleton and may help regulate the activity of brain cells. In Alzheimer's disease, Tau forms abnormal deposits called neurofibrillary tangles, a hallmark pathology of the disease.

By identifying targets that prevent or reverse Tau dysfunction, Bristol-Myers Squibb and Gladstone hope to ident